Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
NCT00052403 · Barbara Ann Karmanos Cancer Institute, Other · Withdrawn
Key facts
| NCT number | NCT00052403 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study of Monoclonal Antibody Anti-Anb3 Integrin in Patients With Advanced Solid Tumors |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Procedure |
| Interventions | monoclonal antibody anti-anb3 integrin, anti-cytokine therapy, antiangiogenesis therapy, antibody therapy, biological response modifier therapy, growth factor antagonist therapy, monoclonal antibody therapy |
| Enrollment | 0 |
| Start date | Feb 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: